Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Aryl Hydrocarbon Receptor is a Target of 17-Allylamino-17-demethoxygeldanamycin and Enhances its Anticancer Activity in Lung Adenocarcinoma Cells

Po-Hung Chen, Jinghua Tsai Chang, Lih-Ann Li, Hui-Ti Tsai, Mei-Ya Shen and Pinpin Lin
Molecular Pharmacology March 2013, 83 (3) 605-612; DOI: https://doi.org/10.1124/mol.112.081646
Po-Hung Chen
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan (P.H.C., J.T.C., P.L.); and Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Zhunan, Taiwan (P.H.C., L.A.L., H.T.T., M.Y.S., P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinghua Tsai Chang
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan (P.H.C., J.T.C., P.L.); and Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Zhunan, Taiwan (P.H.C., L.A.L., H.T.T., M.Y.S., P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lih-Ann Li
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan (P.H.C., J.T.C., P.L.); and Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Zhunan, Taiwan (P.H.C., L.A.L., H.T.T., M.Y.S., P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui-Ti Tsai
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan (P.H.C., J.T.C., P.L.); and Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Zhunan, Taiwan (P.H.C., L.A.L., H.T.T., M.Y.S., P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mei-Ya Shen
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan (P.H.C., J.T.C., P.L.); and Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Zhunan, Taiwan (P.H.C., L.A.L., H.T.T., M.Y.S., P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pinpin Lin
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan (P.H.C., J.T.C., P.L.); and Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Zhunan, Taiwan (P.H.C., L.A.L., H.T.T., M.Y.S., P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We have demonstrated that aryl hydrocarbon receptor (AhR) is overexpressed in lung adenocarcinoma (AD). AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials. Here we investigated whether AhR plays a role in 17-AAG-mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy. AhR expression in lung AD cells was modulated by siRNA interference or overexpression. Tumor growth was determined with colony formation in vitro or in vivo. Anticancer activity of 17-AAG was determined by measuring cell viability, cell cycle distribution, and expression of cell cycle regulators. Proteins and mRNA levels were examined by immunoblotting and the real-time reverse transcription-polymerase chain reaction, respectively. In this study, AhR overexpression positively modulated growth of lung AD cells, at least partially, via RelA-dependent mechanisms. Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG. In addition, 17-AAG treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells. NAD(P)H:quinone oxidoreductase (NQO1), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells. Knockdown of NQO1 expression attenuated the reduction of cell cycle regulators by 17-AAG treatment in AhR overexpressed cells. We demonstrated that AhR protein not only functions as a downstream target of 17-AAG, but also enhances anticancer activity of 17-AAG in lung AD cells.

Footnotes

  • This study was supported by the National Health Research Institutes [Grant EO-101-PP-02] and the National Science Council [Grant NSC 99-2628-B-400-003-MY3].

  • dx.doi.org/10.1124/mol.112.081646.

  • Received July 31, 2012.
  • Accepted December 10, 2012.
  • Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 83 (3)
Molecular Pharmacology
Vol. 83, Issue 3
1 Mar 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Aryl Hydrocarbon Receptor is a Target of 17-Allylamino-17-demethoxygeldanamycin and Enhances its Anticancer Activity in Lung Adenocarcinoma Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

AhR Enhanced 17-AAG Activity in Lung AD

Po-Hung Chen, Jinghua Tsai Chang, Lih-Ann Li, Hui-Ti Tsai, Mei-Ya Shen and Pinpin Lin
Molecular Pharmacology March 1, 2013, 83 (3) 605-612; DOI: https://doi.org/10.1124/mol.112.081646

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

AhR Enhanced 17-AAG Activity in Lung AD

Po-Hung Chen, Jinghua Tsai Chang, Lih-Ann Li, Hui-Ti Tsai, Mei-Ya Shen and Pinpin Lin
Molecular Pharmacology March 1, 2013, 83 (3) 605-612; DOI: https://doi.org/10.1124/mol.112.081646
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics